Morote Juan, Paesano Nahuel, Picola Natàlia, Miró Berta, Abascal José M, Servian Pol, Trilla Enrique, Méndez Olga
Department of Urology, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
Department of Surgery, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Cancers (Basel). 2024 Jun 23;16(13):2306. doi: 10.3390/cancers16132306.
Since the optimal scheme for targeted biopsies of magnetic resonance imaging (MRI) suspicious lesions remains unclear, we compare the efficacy of two schemes for these index lesions. A prospective trial was conducted in 1161 men with Prostate Imaging Reporting and Data System v 2.1 3-5 undergoing targeted and 12-core systematic biopsy in four centers between 2021 and 2023. Two- to four-core MRI-transrectal ultrasound fusion-targeted biopsies via the transperineal route were conducted in 900 men in three centers, while a mapping per 0.5 mm core method (saturated scheme) was employed in 261 men biopsied in another center. A propensity-matched 261 paired cases were selected for avoiding confounders other than the targeted biopsy scheme. CsPCa (grade group ≥ 2) was identified in 125 index lesions (41.1%) when the two- to four-core scheme was employed, while in 187 (71.9%) when the saturated biopsy ( < 0.001) was used. Insignificant PCa (iPCa) was detected in 18 and 11.1%, respectively ( = 0.019). Rates of csPCa and iPCa remained similar in systematic biopsies. CsPCa detected only in systematic biopsies were 5 and 1.5%, respectively ( = 0.035) in each group. The saturated scheme for targeted biopsies detected more csPCa and less iPCa than did the two- to four-core scheme in the index lesions. The rate of csPCa detected only in the systematic biopsies decreased when the saturated scheme was employed.
由于磁共振成像(MRI)可疑病变的靶向活检最佳方案仍不明确,我们比较了两种针对这些索引病变的方案的疗效。2021年至2023年期间,在四个中心对1161名前列腺影像报告和数据系统v 2.1 3-5级的男性进行了前瞻性试验,这些男性同时接受了靶向活检和12针系统活检。三个中心的900名男性通过经会阴途径进行了两到四针MRI-经直肠超声融合靶向活检,而另一个中心对261名接受活检的男性采用了每0.5毫米针的映射方法(饱和方案)。为避免靶向活检方案以外的混杂因素,选择了倾向匹配的261对病例。采用两到四针方案时,125个索引病变(41.1%)中发现临床显著性前列腺癌(csPCa,分级组≥2),而采用饱和活检时(<0.001)为187个(71.9%)。分别在18%和11.1%中检测到意义不显著的前列腺癌(iPCa)(P = 0.019)。系统活检中csPCa和iPCa的发生率保持相似。每组中仅在系统活检中检测到的csPCa分别为5%和1.5%(P = 0.035)。与两到四针方案相比,靶向活检饱和方案在索引病变中检测到更多的csPCa和更少的iPCa。采用饱和方案时,仅在系统活检中检测到的csPCa发生率降低。